Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1647-1659
Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1647
Table 1 Baseline characteristics
Characteristics

Overall (771)
HTGP (241)
ABP (530)
P value
Age (yr)49 (37.0; 63.0)37 (26.0; 53.8)56 (30.0; 84.0)< 0.001
Sex, n (%)< 0.001
Male466 (60.4)184 (76.3)282 (53.2)
Female305 (39.6)57 (23.7)248 (46.8)
BMI (kg/m2)26 (23.4; 28.7)27.8 (22.0; 35.3)25.4 (19.0; 33.7)< 0.001
Smoking, n (%)< 0.001
N515 (66.8)131 (54.4)384 (72.5)
Y256 (33.2)110 (45.6)146 (27.5)
Drinking, n (%)< 0.001
N550 (71.3)147 (61)403 (76)
Y221 (28.7)94 (39)127 (24)
Diabetes, n (%)< 0.001
N643 (83.4)173 (71.8)470 (88.7)
Y128 (16.6)68 (28.2)60 (11.3)
Hypertension, n (%)< 0.001
N581 (75.4)202 (83.8)379 (71.5)
Y190 (24.6)39 (16.2)151 (28.5)
Hyperlipidemia, n (%)< 0.001
N583 (75.6)88 (36.5)495 (93.4)
Y188 (24.4)153 (63.5)35 (6.6)
Laboratory data
ALT63.6 (26.0; 181.3)31.9 (9.7; 111.7)108.8 (13; 616.8)< 0.001
AST46.2 (24.4; 130.2)28.8 (13.0; 114.1)70.1 (16.1; 638.0)< 0.001
ALP108.9 (79.1; 108.9)101.1 (41.9; 118.1)108.9 (55.3; 258.5)< 0.001
γ-GT219.5 (119.7; 219.5)219.5 (17.6; 318.2)219.5 (31.0; 696.6)< 0.001
ALB36.4 (31.8; 41.4)37.0 (21.6; 48.6)36.3 (18.3; 48.3)0.018
TBIL23.7 (14.4; 36.7)19.9 (3.0; 44.4)27.1 (5.1; 106.1)< 0.001
DBIL8.8 (3.8; 13.4)4.0 (0.6; 15.1)11.2 (2.5; 67.2)< 0.001
TC4.8 (3.4; 5.4)6.8 (3.3; 17.7)4.0 (1.0; 5.5)< 0.001
TG1.9 (0.9; 3.9)7.4 (1.0; 38.8)1.1 (0.3; 3.9)< 0.001
SCr75.9 (62.9; 86.9)79.0 (43.4; 157.4)75.0 (48.4; 127.3)0.174
AMY256.0 (82.6; 729.5)191.6 (30.0; 927.5)343.1 (38.4; 2053.5)< 0.001
LPS344.3 (97.7; 878.8)323.2 (47.5; 1312.0)391.9 (28.4; 1709.6)0.15
PT-S12.8 (11.9; 13.3)12.2 (10.7; 14.4)12.9 (11.1; 16.0)< 0.001
FIB4.4 (3.3; 5.2)5.2 (2.6; 9.0)4.1 (2.4; 6.9)< 0.001
WBC11.1 (7.7; 14.5)11.8 (5.8; 21.0)10.6 (4.6; 20.2)< 0.001
Lym1.1 (0.7; 1.5)1.3 (0.7; 3.1)1.0 (0.4; 2.1)< 0.001
RBC4.6 (4.1; 5.1)5.0 (4.0; 6.1)4.4 (3.4; 5.7)< 0.001
RDW13.3 (12.5; 14.1)13.2 (9.8; 14.4)13.5 (9.9; 16.2)0.003
PLT203.0 (164.0; 254.0)223.0 (134.1; 391.0)197.0 (103.6; 339.4)< 0.001
PDW16.8 (16.3; 17.4)17.3 (12.8; 19.1)16.6 (11.8; 18.1)< 0.001
NLR8.3 (4.5; 14.2)6.9 (1.6; 18.9)9.1 (2.1; 33.1)< 0.001
PLR184.3 (131.6; 273.6)160.5 (70.3; 379.0)203.1 (83.4; 518.6)< 0.001
Atlanta classification, n (%)0.001
MAP437 (56.7)125 (51.9)312 (58.9)
MSAP156 (20.2)40 (16.6)116 (21.9)
SAP178 (23.1)76 (31.5)102 (19.2)
Scoring systems
MCTSI4.0 (2.0; 6.0)4.0 (2.0; 8.0)4.0 (2.0; 8.0)0.005
JSS1.0 (0; 2.0)1.0 (0; 4.0)1.0 (0; 4.0)0.029
BISAP1.0 (0; 1.0)0 (0; 2.0)1.0 (0; 2.0)< 0.001
Modified Marshall2.0 (1.0; 4.0)2.0(0; 5.9)2.0 (0; 7.0)0.049
SOFA1.0 (0; 3.0)1.0 (0; 4.0)1.0 (0; 5.0)0.163
POF, n (%)0.247
N537 (69.6)161 (66.8)376 (70.9)
Y234 (30.4)80 (33.2)154 (29.1)
SIRS, n (%)0.956
N465 (60.3)145 (60.2)320 (60.4)
Y306 (39.7)96 (39.8)210 (39.6)
Hospital stay (d)13.5 (9.4; 19.2)12.0 (5.2; 29.3)14.3 (5.4; 36.1)< 0.001
Mortality, n (%)0.556
N762 (98.8)239 (99.2)523 (98.7)
Y9 (1.2)2 (0.8)7 (1.3)
Table 2 Correlation analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in hypertriglyceridemia-induced acute pancreatitis
Parameters
PLR
P value
NLR
P value
Atlanta classification0.0000.005
Mild/moderate152.1 (110.8; 198.0)6.3 (3.5; 10.2)
Severe188.2 (137.9; 265.6)7.9 (5.5; 12.6)
MCTSI0.0870.235
    < 4150.6 (113.4; 197.4)6.1 (3.4; 10.1)
    ≥ 4161.7 (119.1; 240.6)7.0 (4.4; 11.2)
JSS0.7540.815
    < 3159.0 (119.9; 228.0)6.9 (3.9; 11.2)
    ≥ 3161.2 (108.2; 257.6)7.0 (5.0; 10.2)
BISAP0.3840.395
    < 3159.1 (119.0; 228.4)6.9 (4.0; 10.9)
    ≥ 3171.6 (136.7; 244.4)9.1 (5.8; 12.9)
Modified Marshall0.1670.813
    < 2156.2 (113.4; 214.1)6.8 (3.8; 11.6)
    ≥ 2165.1 (132.0; 239.1)7.0 (4.9; 10.3)
SOFA0.0110.005
    < 3155.6 (113.2; 214.9)6.4 (3.6; 10.1)
    ≥ 3175.0 (136.0; 259.6)8.0 (5.9; 12.8)
Table 3 Correlation Analysis of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio with the acute pancreatitis Scoring System in acute biliary pancreatitis
Parameters
PLR
P value
NLR
P value
Atlanta classification0.0020.000
Mild/moderate194.0 (136.2; 286.2)8.1 (4.3; 13.8)
Severe239.1 (171.0; 358.9)16.0 (8.9; 21.8)
MCTSI0.0210.000
    < 4190.8 (135.4; 268.6)7.4 (4.0; 12.8)
    ≥ 4212.7 (145.3; 322.9)11.2 (6.0; 17.6)
JSS0.0060.000
    < 3194.5 (139.2; 287.6)8.2 (4.3; 14.2)
    ≥ 3250.6 (150.7; 359.1)16.5 (8.7; 22.9)
BISAP0.9210.002
    < 3203.8 (141.9; 295.9)8.9 (4.5; 15.7)
    ≥ 3192.9 (130.4; 329.9)15.6 (11.2; 20.4)
Modified Marshall0.0150.000
    < 2181.2 (134.0; 272.3)6.0 (3.5; 12.0)
    ≥ 2217.2 (145.2; 314.6)11.3 (6.2; 18.3)
SOFA0.5550.000
    < 3198.5 (140.4; 296.4)8.2 (4.1; 14.5)
    ≥ 3212.2 (142.1; 311.3)12.4 (7.3; 19.3)
Table 4 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in hypertriglyceridemia-induced acute pancreatitis
ParametersAUC95%CI
SensitivitySpecificityP value
Lower
Upper
MCTSI0.7180.6490.7860.6500.733< 0.001
JSS0.7030.6310.7750.6630.720< 0.001
BISAP0.7050.6340.7750.7250.652< 0.001
Modified Marshall0.7720.7080.8350.6630.795< 0.001
SOFA0.8270.7720.8820.7130.820< 0.001
PLR0.6220.5460.6990.4130.8260.002
NLR0.6190.5460.6930.8000.7200.003
Table 5 Predictive performance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the acute pancreatitis Scoring System for the occurrence of persistent organ failure in acute biliary pancreatitis
ParametersAUC95%CI
SensitivitySpecificityP value
Lower
Upper
MCTSI0.5730.5170.6290.4090.7290.008
JSS0.7600.7150.8050.5910.782< 0.001
BISAP0.6940.6450.7430.4480.827< 0.001
Modified Marshall0.7610.7170.8040.6750.705< 0.001
SOFA0.7460.7030.7890.9420.465< 0.001
PLR0.5690.5160.6210.7270.4180.013
NLR0.6680.6180.7170.5320.761< 0.001